[PP.13.08] COLECALCIFEROL DOES NOT LOWER BLOOD PRESSURE ON TOP OF OPTIMAL USUAL CARE IN VITAMIN D DEFICIENT PATIENTS WITH HYPERTENSION

    loading  Checking for direct PDF access through Ovid

Abstract

Objective:

A low vitamin D status is very common and has also been considered as a risk factor for hypertension and cardiovascular disease, possibly related to activation of the renin-angiotensin-aldosteron-system. However, the antihypertensive effect of colecalciferol on blood pressure has been inconclusive. We studied the additional effect of cholecalciferol on the systolic blood pressure of patients visiting our outpatient hypertension clinic.

Design and method:

A single centre, randomized, double blind, placebo controlled trial was performed. Patients with a systolic blood pressure above 140 mmHg and a 25OHD level between 20–50 nmol/L were randomized to 2000 IE cholecalciferol or placebo daily for 12 months. Usual antihypertensive treatment was continued. Ambulatory blood pressure and laboratory measurements were performed at baseline, 6 and 12 months.

Results:

A total of 109 participants were included and randomized in this study. Mean 25OHD levels were 43 nmol/L in the placebo group and 103 nmol/L in the vitamin D group after 12 months (p < 0,0001). Mean 24 hour systolic blood pressure was 127 mmHg in the placebo group and 125 mmHg in the vitamin D group after 12 months (p = 0,3453). No difference was found for the total amount of antihypertensive medication that was used at 6 and 12 months. Mean PTH was significantly lower (p = 0,0188) in the vitamin D group (4,8 pmol/L) compared to the placebo group (6,0 pmol/l). There was no significant treatment effect on mean aldosterone and renin levels.

Conclusions:

Adequate vitamin D supplementation did not significantly lower blood pressure on top of optimal usual care in vitamin D deficient patients with hypertension

Related Topics

    loading  Loading Related Articles